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Abstract 
Background: To examine the association between circulating 25(OH)D concentrations and incidence of total hip 
replacement for osteoarthritis in a prospective cohort study.
Methods: This study examined a random sample of 2651 participants in the Melbourne Collaborative Cohort Study 
who had 25(OH)D concentrations measured from dried blood spots collected in 1990-1994. Participants who under-
went total hip replacement for osteoarthritis between January 2001 and December 2018 were identified by linking 
the cohort records to the Australian Orthopaedic Association National Joint Replacement Registry. Cox proportional 
hazard regression was used to estimate hazard ratios (HR) and 95% confidence intervals (CI) of total hip replacement 
for osteoarthritis in relation to 25(OH)D concentrations, adjusted for confounders.
Results: Eighty-six men and eighty-seven women had a total hip replacement for osteoarthritis. Compared with 
men in the lowest (1st) quartile of 25(OH)D concentration, the HR for total hip replacement was 2.32 (95% CI 1.05, 
5.13) for those in the 2nd quartile, 2.77 (95% CI 1.28, 6.00) for those in the 3rd quartile, and 1.73 (95% CI 0.75, 4.02) for 
those in the highest quartile of 25(OH)D concentrations (p for trend 0.02). There was little evidence of an association 
in women.
Conclusions: Higher circulating 25(OH)D concentrations were associated with an increased risk of total hip replace-
ment for osteoarthritis in men but not in women. Although the underlying mechanism warrants further investiga-
tion, our findings highlight the need to determine the optimal levels of circulating 25(OH)D to reduce the risk of hip 
osteoarthritis.
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Background
Hip osteoarthritis (OA) causes pain and disability and is a 
common musculoskeletal condition that affects millions 
of people worldwide. The lifetime risk of symptomatic 
hip OA is 18.5% for men and 28.6% for women [1]. There 
are no effective treatments for hip OA that alter disease 
process; as a result the prevalence and burden of disease 
due to hip OA are increasing. Costly total hip replace-
ments are used to treat symptomatic end-stage hip OA, 
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but 7 to 23% of patients experience ongoing pain despite 
technically successful surgery [2]. Therefore the strategy 
for reducing the burden of hip OA lies in shifting the 
management paradigm from palliation to disease preven-
tion and reduction of disease progression.
As the hip is a ball and socket joint, it is susceptible to 
altered hip bone shape and joint congruency, which are 
important risk factors for the development and progres-
sion of hip OA [3]. Vitamin D is critical in bone min-
eralization, remodelling, and maintenance and thus is 
capable of changing bone shape [4]. Serum or plasma 
25-hydroxyvitamin D [25(OH)D] concentration is con-
sidered the best indicator of vitamin D status [5]. Previ-
ous studies have examined whether circulating 25(OH)
D concentrations are associated with hip OA in popula-
tions at risk of osteoporosis [6, 7] or community-based 
populations [8–10]. Two studies reported that low serum 
levels of 25(OH)D were associated with increased preva-
lence and incidence of radiographic hip OA among men 
and women aged ≥65 years (mean age 73.5 years, stand-
ard deviation 5.8 years) [6, 7]. However, there is uncer-
tainty regarding the generalizability of these results. In 
the Study of Osteoporotic Fractures, women who had 
low incidence of fracture were excluded [6, 11], and in 
the Osteoporotic Fractures in Men Study, 17% of partici-
pants reported a fracture in the year prior to recruitment 
[7, 12], indicating the presence of selection bias towards 
high risk of fracture in both studies. The three commu-
nity-based cohort studies not primarily aimed at examin-
ing osteoporosis [8–10] are summarized in Table 1. One 
Finnish study of 805 participants found no association 
between circulating 25(OH)D concentrations and the 
incidence of hip OA, based on 40 cases of hip OA [10]. 
In contrast, another Finnish study of 5274 participants 
showed a trend of increased risk of hip OA associated 
with increasing circulating 25(OH)D concentrations, but 
this study was based on only 45 cases of hip OA [9]. In 
an Australian study of 9135 participants, we found that 
higher concentrations of circulating 25(OH)D were asso-
ciated with increased risk of hip replacement for severe 
OA in men but not in women [8]. We used a robust defi-
nition of hip OA, i.e. hip replacement for OA, which in 
the context of the Australian healthcare system is a valid 
measure of severe hip OA, as all Australian citizens and 
permanent residents have access to quality health care 
services under Australia’s publicly funded universal 
health insurance system (Medicare). Furthermore, our 
study had a large number of joint replacements, increas-
ing the power to show potential associations [8].
Given the major focus on targeting vitamin D for the 
prevention of osteoporosis, understanding the effect 
of vitamin D on the risk of hip OA will be important 
to inform public health recommendations. As there is 
uncertainty regarding the association between circulating 
25(OH)D concentrations and hip OA, we used a different 
well-established cohort study, with participants recruited 
from the community independent of any musculoskel-
etal disease, and long-term follow-up with enriched data 
prospectively collected [13], to investigate whether circu-
lating 25(OH)D concentrations are associated with the 
incidence of total hip replacement for severe OA.
Methods
Participants
The Melbourne Collaborative Cohort Study (MCCS) is 
a prospective cohort study of 41,513 participants aged 
27-75 years, recruited via the electoral roll, advertise-
ments and community announcements in local media 
between 1990 and 1994, aimed at investigating the roles 
of diet and lifestyle in cancer and other non-communi-
cable diseases [13, 14]. The study protocol was approved 
by the Cancer Council Victoria Human Research Ethics 
Committee (IEC No. 9001). Participants gave written 
informed consent to participate and for the investigators 
to obtain access to their medical records.
A case-cohort study nested within the MCCS was set 
up to investigate 25(OH)D in relation to breast, prostate, 
and colorectal cancers, diabetes, and mortality. Eligibility 
for the case-cohort study was restricted to participants 
who had dried blood spot samples available and no diag-
nosis of cancer prior to recruitment (n eligible = 29,205). 
As part of the case-cohort study, a sex-stratified random 
sample of 2996 eligible participants was selected as the 
“subcohort”. The current investigation involves this ran-
dom sample of subcohort participants. All methods were 
carried out in accordance with relevant guidelines and 
regulations.
Identification of hip replacement
Participants with a primary total hip replacement were 
identified from the Australian Orthopaedic Associa-
tion National Joint Replacement Registry (AOA NJRR). 
The Registry began data collection in September 1999 
and implementation was introduced in a staged fashion 
in each of the Australian states and territories. Victo-
ria commenced data collection in January 2001 and the 
AOA NJRR has collected national data on joint replace-
ment procedures performed in Australia since 2002 
[15]. The Registry has detailed information on the joint 
replacement prostheses, patient demographics, the rea-
son for joint replacement, whether it is a primary joint 
replacement or a revision and the type of revision. Data 
are collected from both public and private hospitals and 
this is validated using a sequential multi-level matching 
process against State and Territory Health Department 
unit record data [15]. Following the validation process 
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and retrieval of unreported records, the Registry col-
lects an almost complete set of data relating to hip and 
knee replacements in Australia [15]. Identifying infor-
mation for MCCS participants, including first name, last 
name, date of birth, and sex, was provided to the staff at 
the AOA NJRR in order to identify MCCS participants 
who had undergone a joint replacement between 1 Jan-
uary 2001 and 31 December 2018. The matching was 
performed on these data provided using the Freely Exten-
sible Biomedical Record Linkage (Febrl) system. Exact 
matches were identified and probabilistic matches were 
reviewed. The data linkage study protocol was approved 
by the Human Research Ethics Committees of Cancer 
Council Victoria (HREC 0601), and Monash University 
(2006000608).
Demographic, lifestyle factors, medical history, 
and anthropometrics
At recruitment, data on demographic (sex, date of birth, 
country of birth) and lifestyle factors (physical activ-
ity, smoking status), Socio-Economic Indexes For Areas 
(SEIFA) index of relative disadvantage in quintile groups, 
and medical history (diabetes and hypertension) were 
collected using questionnaires in face-to-face inter-
views [13]. Physical activity was assessed by three sepa-
rate questions obtained from the Risk Factor Prevalence 
Study conducted by the National Heart Foundation and 
Australian Institute of Health regarding frequency of 
non-occupational vigorous and moderate physical activ-
ity, and walking [16, 17]. Participants were categorised as 
whether or not participating in vigorous activity in line 
with values published in the Compendium of Physical 
Activities [18]. Height and weight were measured accord-
ing to written protocols based on standard procedures, 
and body mass index (BMI) was calculated [13]. Data on 
self-reported knee and hip replacement were collected at 
the second wave of active follow-up (2003-2007).
Circulating 25(OH)D measurement
Blood samples were collected, and for participants 
recruited from the second year of recruitment onwards 
(i.e. for approximately 75% of participants), whole blood 
was spotted onto Whatman 903 paper. Spots were air 
dried and then stored in the dark. Circulating 25(OH)
D concentrations were measured from dried blood 
spots using liquid chromatography-tandem mass spec-
trometry (LC-MS/MS) as previously described [19, 20]. 
The laboratory uses National Institute of Standards and 
Technology (NIST) Vitamin D Standard Reference Mate-
rials and participates in the Vitamin D External Qual-
ity Assessment Scheme (DEQAS). It has been shown 
that measurement of 25(OH)D in dried blood spots is a 
valid and reliable alternative to conventional serum or 
plasma measurement [19]. Importantly, a simple calibra-
tion model has been developed to convert dried blood 
spot measurements to equivalent plasma concentra-
tions, facilitating comparisons against clinical reference 
ranges and with studies using sera or plasma samples 
[19]. Measured 25(OH)D concentrations in dried blood 
spots were corrected for batch effects and seasonal vari-
ation and converted to plasma-equivalent concentrations 
as previously described [21]. All results presented are for 
batch- and season-adjusted plasma-equivalent 25(OH)D 
concentrations.
Statistical analysis
Participants were excluded if 25(OH)D measurements 
were not performed (n = 10); they died or left Australia 
before January 2002; they reported at the second wave 
of follow-up (2003-2007) having had a joint replacement 
prior to 1 January 2001; left Australia before the date of 
a primary joint replacement; their first recorded proce-
dure in the AOA NJRR was a revision joint replacement 
(n = 335) (Fig. 1).
Characteristics and the number of hip replacements in 
participants who were included in the current study and 
all other MCCS participants were compared. Character-
istics of study participants were tabulated based on sex 
and hip replacement for OA. Cox proportional hazards 
regression analyses were used to estimate hazard ratios 
(HRs) and 95% confidence intervals (CIs) for hip replace-
ment due to OA in relation to 25(OH)D concentrations, 
with age as the time scale. Follow-up for total hip replace-
ment for OA (i.e. calculation of person-time) began on 
1 January 2001, and ended at the date of first total hip 
replacement for OA or date of censoring. Participants 
were censored at the date of first total hip replacement 
performed for indications other than OA including hip 
fracture, avascular necrosis; the date of first total knee 
replacement; the date of death; the date the participant 
left Australia; or end of follow-up (i.e. 31 December 2018, 
the date that ascertainment of joint replacement by the 
AOA NJRR was complete); whichever came first. The lin-
ear association between circulating 25(OH)D concentra-
tions and total hip replacement for OA was examined by 
fitting 25(OH)D as a continuous variable, and reported 
per 25 nmol/L increment. Circulating 25(OH)D concen-
trations were also categorized into sex-specific quartiles. 
The lowest quartile was used as the referent category. 
For tests of linear trend, participants were assigned the 
median value in each quartile, and the corresponding 
variable was modelled continuously.
To test whether the association between 25(OH)D con-
centrations and total hip replacement for OA was modi-
fied by sex, interactions were fitted and tested using the 
likelihood ratio test. Since there was evidence for an 
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interaction (p = 0.06), all analyses were performed for 
men and women separately, and adjusted for BMI (kg/m2, 
modelled continuously), vigorous physical activity (any vs 
no), smoking status (former/current vs never), country of 
birth (Australia/United Kingdom vs Italy/Greece), socio-
economic disadvantage (quintiles of Socio-Economic 
Indexes for Areas [SEIFA], most deprived [quintiles 1-3] 
vs least deprived [quintiles 4-5]), and co-morbidities (yes 
vs no): diabetes and hypertension. All statistical analyses 
were performed using Stata 15.0 SE (StataCorp LP., Col-
lege Station, TX, USA).
Results
Participants of the current study were younger (53.7 ± 8.7 
vs. 55.1 ± 8.6 years), more likely to be men (54.6% vs 
39.1%), to be born in Australia and UK (84.7% vs 75.3%), 
to participate in vigorous physical activity (25.9% vs 
21.1%), to be former/current smokers (54.0% vs 41.5%), 
to be in the upper two (least disadvantaged) quintiles of 
SEIFA (53.6% vs 45.6%), and less likely to have hyperten-
sion (17.7% vs 21.5%) and diabetes (2.5% vs. 3.5%), com-
pared with MCCS participants who were not included in 
the analysis. There was no significant difference in preva-
lence of total hip replacement for OA between the two 
groups (6.5% vs. 5.7%).
One hundred and seventy three participants (86 
men and 87 women) had a total hip replacement for 
OA from January 2001 until December 2018, a mean 
follow-up of 15.7 (SD 4.6) years. The characteristics of 
the participants are presented in Table  2. Compared 
with men without a total hip replacement, men with a 
total hip replacement were less likely to be in the low-
est 25(OH)D quartile and more likely to be in the 3rd 
25(OH)D quartile, more likely to be least deprived and 
participate in vigorous physical activity, and less likely 
to be current/former smokers. Women having a hip 
replacement did not noticeably differ with respect to 
levels of 25(OH)D or other variables with those who 
did not have a hip replacement.
In men, the HR for total hip replacement for OA was 
1.23 (95% CI 0.95-1.60) per 25 nmol/L increment in 
25(OH)D concentration after adjusting for BMI, vigor-
ous physical activity, smoking status, country of birth, 
and SEIFA (Table  3). Compared with men in the low-
est (1st) quartile of 25(OH)D concentration, the HR for 
total hip replacement for OA was 2.06 (95% CI 1.02, 4.13) 
for those in the 2nd quartile, 2.40 (95% CI 1.21, 4.75) for 
those in the 3rd quartile, and 1.57 (95% CI 0.75, 3.29) for 
those in the highest quartile of 25(OH)D concentrations 
(p for trend 0.04). Additional adjustment for co-mor-
bidities (diabetes and hypertension) did not change the 
Fig. 1 Flowchart of Melbourne Collaborative Cohort Study participants included in the analyses
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Table 2 Characteristics of study participants at recruitment
OA osteoarthritis, 25(OH)D 25-hydroxyvitamin D, IQR interquartile range, M male, F female, SD standard deviation, SEIFA Socio-Economic Indexes for Areas
Men Women
Total hip replacement for OA Total hip replacement for OA
No Yes No Yes
Number of participants 1379 86 1099 87
25(OH)D (nmol/L), median (IQR) 54.5 (42.7-69.0) 57.0 (47.3-66.4) 42.8 (34.7-52.7) 44.6 (34.5-53.3)
25(OH)D Quartile, n (%)
 1 (M < 43.00; F < 34.80 nmol/L) 354 (25.7) 12 (13.9) 279 (25.3) 23 (26.4)
 2 (M 43.00- < 54.85; F 34.80- < 42.92 nmol/L) 346 (25.1) 24 (27.9) 278 (25.3) 19 (21.8)
 3 (M 54.85- < 69.22; F 42.92- < 53.04 nmol/L) 337 (24.4) 31 (36.1) 272 (24.8) 23 (26.4)
 4 (M ≥ 69.22; F ≥ 53.04 nmol/L) 342 (24.8) 19 (22.1) 270 (24.6) 22 (25.3)
Age (years), mean (SD) 53.5 (9.0) 55.4 (8.2) 53.3 (8.6) 56.6 (8.1)
Body mass index (kg/m2), mean (SD) 26.8 (3.5) 28.1 (3.2) 26.1 (5.0) 26.8 (4.4)
Country of birth, n (%)
 Australia/United Kingdom 1129 (81.9) 73 (84.9) 948 (86.3) 79 (90.8)
 Italy/Greece 250 (18.1) 13 (15.1) 151 (13.7) 8 (9.2)
Socioeconomic status (SEIFA), n (%)
 Most deprived (quintiles 1-3) 678 (49.4) 37 (43.0) 475 (43.3) 38 (43.7)
 Least deprived (quintiles 4-5) 694 (50.6) 49 (57.0) 621 (56.7) 49 (56.3)
Vigorous physical activity, n (%) 360 (26.1) 31 (36.1) 269 (24.5) 22 (25.3)
Smoking (former/current), n (%) 766 (55.6) 41 (47.7) 355 (32.3) 34 (39.1)
Diabetes, n (%) 58 (4.9) 2 (2.8) 22 (2.3) 1 (1.3)
Hypertension, n (%) 257 (21.5) 16 (22.5) 212 (21.8) 20 (25.6)
Table 3 Hazard ratios of total hip replacement for osteoarthritis in relation to circulating 25-hydroxyvitamin D concentrations
25(OH)D 25-hydroxyvitamin D, HR hazard ratio, CI confidence interval
a adjusted for BMI, vigorous physical activity, smoking status, country of birth, and SEIFA
b adjusted for BMI, vigorous physical activity, smoking status, country of birth, SEIFA, and co-morbidities (diabetes and hypertension)
Model  1a, HR (95% CI) Model  2b, HR (95% CI)
Men
 25(OH)D (per 25 nmol/L increment) 1.23 (0.95-1.60) p = 0.12 1.26 (0.95-1.67) p = 0.11
25(OH)D Quartiles
 1 (<43.00 nmol/L) Reference Reference
 2 (43.00 to <54.85 nmol/L) 2.06 (1.02-4.13) 2.32 (1.05-5.13)
 3 (54.85 to <69.22 nmol/L) 2.40 (1.21-4.75) 2.77 (1.28-6.00)
 4 (≥69.22 nmol/L) 1.57 (0.75-3.29) 1.73 (0.75-4.02)
P for trend 0.04 0.02
Women
 25(OH)D (per 25 nmol/L increment) 0.97 (0.64-1.47) p = 0.90 0.94 (0.60-1.47) p = 0.78
25(OH)D Quartiles
 1 (<34.8 nmol/L) Reference Reference
 2 (34.8 to <42.92 nmol/L) 0.74 (0.40-1.37) 0.60 (0.32-1.16)
 3 (42.92 to <53.04 nmol/L) 0.92 (0.51-1.66) 0.79 (0.43-1.47)
 4 (≥53.04 nmol/L) 0.86 (0.47-1.57) 0.77 (0.41-1.44)
P for trend 0.93 0.34
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results. In women, there was little evidence of an associa-
tion (Table 3).
Discussion
In this population-based cohort of middle-aged and older 
individuals, higher circulating 25(OH)D concentrations 
were associated with an increased risk of having a total 
hip replacement for OA in men but not in women, con-
firming our previous findings from an independent com-
munity-based cohort study [8].
In the Australian Diabetes, Obesity and Lifestyle Study 
of 9135 participants followed up for 9.1 (SD 2.7) years, 
we found an increased risk of having a hip replacement 
for OA with higher serum 25(OH)D concentrations in 
men but not women [8]. The current study examining an 
independent cohort, the MCCS, with a follow-up of 15.7 
(SD 4.6) years, observed similar findings when hip OA 
was defined as hip replacement acquired from linking 
the cohort to NJRR. These linkage data are validated [22] 
and nearly complete (>99%) regarding joint replacements 
in Australia [15]. Our findings from the two Australian 
cohort studies are supported by findings from the Finland 
Health 2000 study which showed that higher concentra-
tions of 25(OH)D were associated with an increased risk 
of developing hip OA [9]. However the Finnish study had 
only 45 cases of incident hip OA so was underpowered to 
examine sex differences [9].
The mechanism for the association between higher 
25(OH)D concentrations and increased risk of hip 
replacement for OA is not clear. Vitamin D plays an 
important role in bone mineralization, remodelling and 
maintenance, and greater serum 25(OH)D concentra-
tions are associated with increased bone mineral den-
sity [23, 24]. The effect of vitamin D on anabolic bone 
changes might lead to subchondral bone sclerosis and 
altered hip bone shape. There is increasing evidence 
that hip bone shape is modifiable and subtle changes in 
hip bone shape increase the risk of hip OA [3, 25], and 
that increased bone mineral density is a risk factor for 
hip OA [26]. The sex difference that we observed for the 
association between circulating 25(OH)D concentrations 
and severe hip OA may be mediated through circulating 
levels of testosterone and estrogen, since these hormones 
play a role in regulating vitamin D and calcium homeo-
stasis [27]. Similarly, vitamin D is known to affect andro-
gen synthesis in testicular cells in men [28], and possibly 
ovarian androgens and testosterone levels in women [29]. 
Other studies have also reported sex-dependent skeletal 
effects of vitamin D [30]. We have shown a link between 
sex steroid hormones and total hip replacement for OA 
[22, 31]. Sex differences in adiposity and body fat dis-
tribution might be another possible explanation. In our 
study, the HR for the association between 25(OH)D and 
THR was lower in the highest quartile compared with 
the HRs of the middle two quartiles, which is compa-
rable to the biphasic relationship seen between 25(OH)
D and chronic diseases such as cardiovascular disease 
[32], schizophrenia [33], and mortality [34]. However, 
any potential biphasic relationship between 25(OH)D 
and THR, if exists, needs to be interpreted with caution 
given the small numbers of observations of THRs in each 
of the 25(OH)D quartiles in our study. It might mean that 
genetic and environmental factors relating to 25(OH)D 
play a role in OA pathogenesis as has been seen in case of 
bone health [35].
This study has limitations. Although circulating 
25(OH)D concentrations were measured for a random 
sample of MCCS participants, there were some differ-
ences between participants included in this study and 
the rest of MCCS participants. However, it is unlikely 
that the selection of participants for the current study 
would affect the relationship between 25(OH)D and risk 
of total hip replacement for OA. Whilst participants 
with 25(OH)D measured had better health and higher 
socioeconomic position compared with those without 
measurements, the risks of hip replacement were simi-
lar in the two groups. Circulating 25(OH)D concentra-
tions were measured at a single time point (i.e. MCCS 
recruitment). There is good intra-individual consist-
ency in 25(OH)D concentrations measured several years 
apart, thus a single measurement is a reasonable meas-
ure of long-term vitamin D status [36–38]. Furthermore, 
in middle-aged Caucasian adults the main determinants 
of circulating 25(OH)D concentration are sex, age, obe-
sity, latitude, season of blood collection, physical activity, 
and sun exposure [39, 40]. Our study includes commu-
nity-based people of European descent, living in a simi-
lar latitude (all living in Melbourne); we have performed 
sex-specific analysis, adjusted for age, BMI, physical 
activity; and measurements of 25(OH)D were corrected 
for season of blood collection. Thus any misclassifica-
tion associated with single time measurement of 25(OH)
D and total hip replacement for OA is likely to be non-
differential in nature. We could not control for occu-
pational activity, since the MCCS did not have detailed 
information such as heavy lifting and climbing which are 
established risk factors for hip OA. We defined hip OA 
based on joint replacement which reflects end-stage joint 
disease, and thus less severe OA was not captured. It is 
possible that there is residual or unmeasured confound-
ing, for example activities that might influence hip injury. 
We did not have accurate hip replacement data prior to 
2001. It is possible that hip replacement occurring before 
2001 might represent more rapidly progressive disease, 
yet we were only able to assess hip replacement for OA 
occurring after this time and cases in the first few years 
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of follow-up were missed, this would have resulted in 
non-differential misclassification. Although it has been 
suggested that people who uses painkillers i.e. paraceta-
mol, non-steroidal anti-inflammatory drugs (NSAIDs) 
and acetylsalicylic acid might have lower levels of vita-
min D [41], the Danish Osteoporosis Prevention Study 
could not identify any difference in circulating levels of 
25(OH)D between participants who were using pain kill-
ers and those who were not using pain killers (24.3 (11.4) 
ng/ml vs 25.2 (12.3) ng/ml; p = 0.34) [42]. Furthermore, if 
pain killers were an explanatory factor in this study, we 
would have found more THR in those who had lower lev-
els of circulating 25(OH)D which was not the case. Data 
on vitamin D supplementation were lacking. However, 
at the time of MCCS recruitment (1990-1994), supple-
ment use in Australia was uncommon (16% of MCCS 
participants reported using multivitamins at baseline), 
and this is unlikely to fully explain the observed associa-
tion. Screening for vitamin D deficiency and vitamin D 
supplement use have increased since the early 2000s [43]. 
However, fluctuations in 25(OH)D measurements with 
differences between participants along time cannot be 
ruled out. Strengths of our study include its prospective 
cohort study design, validated and reliable measurement 
of circulating 25(OH)D concentrations [19], adjustment 
for important confounders, and the validation and com-
pleteness of AOA NJRR data on hip replacement for OA.
Internationally there is a major focus on targeting 
vitamin D deficiency in order to reduce the burden of 
osteoporotic fractures. However, the ideal concentra-
tion of 25(OH)D is still debated since some experts sug-
gest concentrations less than 50 nmol/L are “insufficient” 
while others consider less than 75 nmol/L as “insufficient” 
[44–46]. There is increasing evidence that associations 
between 25(OH)D and chronic diseases, if they do exist, 
are non-linear. For example, in a meta-analysis, risk of 
cardiovascular disease decreased with increasing 25(OH)
D concentration up to 60 nmol/L, above which there was 
no further decrease or increase [47]. In a randomized 
controlled trial of community-dwelling women aged 
70 years or older, annual oral administration of high-
dose cholecalciferol (vitamin  D3) resulted in an increased 
risk of falls and fractures [48]. Taken together, these data 
highlight the need for further research to determine the 
optimal 25(OH)D concentrations for preventing frac-
tures in different populations and reducing the risk of 
other chronic diseases.
Conclusions
This study confirms our previous results that greater 
circulating 25(OH)D concentrations were associated 
with an increased risk of total hip replacement for OA 
in men but not in women. Further work is needed to 
understand the mechanisms underlying these find-
ings. Our findings also highlight the need to determine 
the optimal levels of circulating 25(OH)D in order to 
reduce the risk of chronic diseases such as hip OA.
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